To include your compound in the COVID-19 Resource Center, submit it here.

Gilead HCV sales short of expectations in 1Q16

Gilead Sciences Inc. (NASDAQ:GILD) slipped $5.35 to $91.65 in early after-hours trading Thursday after it reported 1Q16 earnings that missed analysts' estimates, in part due to lower than

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE